

GLAXOSMITHKLINE PLC  
Form 6-K  
February 10, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 10 February 2017

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No

GlaxoSmithKline plc

Blocklisting Application

Application has been made to the Financial Conduct Authority and the London Stock Exchange Plc for a total of 600,000 Ordinary shares of 25p each (shares) to be admitted to the Official List.

These shares are being reserved under block listings and will be issued as a result of the award of shares pursuant to the following scheme:

Scheme	Shares
GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan	600,000

When issued, these shares will rank pari passu with the existing ordinary shares.

Victoria Whyte  
Company Secretary

10 February 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 10, 2017

By: VICTORIA WHYTE

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc